Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in MontrÃ©al, Canada.

Date	Fund	Action	%
2023/02/13	ARKG	Buy	0.0064
2023/02/10	ARKG	Buy	0.0674
2023/02/09	ARKG	Buy	0.0498
2023/02/08	ARKG	Buy	0.0111
2023/02/07	ARKG	Buy	0.0009
2023/02/06	ARKG	Buy	0.0022
2023/02/03	ARKG	Buy	0.021
2023/02/02	ARKG	Buy	0.0004
2023/02/01	ARKG	Buy	0.0017
2023/01/31	ARKG	Buy	0.0014
2023/01/30	ARKG	Buy	0.0074
2023/01/27	ARKG	Buy	0.0007
2023/01/26	ARKG	Buy	0.012
2023/01/23	ARKG	Buy	0.0048
2021/09/10	ARKG	Buy	0.03
2021/09/09	ARKG	Buy	0
2021/09/08	ARKG	Buy	0
2021/09/07	ARKG	Buy	0.03
2021/09/03	ARKG	Buy	0.02
2021/09/01	ARKG	Buy	0.0013
2021/08/31	ARKG	Buy	0.021
2021/08/30	ARKG	Buy	0.0003
2021/08/27	ARKG	Buy	0.003
2021/08/26	ARKG	Buy	0.001
2021/08/24	ARKG	Buy	0.0001
2021/08/20	ARKG	Buy	0.0012
2021/08/19	ARKG	Buy	0.0076
2021/08/18	ARKG	Buy	0.0016
2021/08/17	ARKG	Buy	0.0037
2021/08/05	ARKG	Buy	0.0002